Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024,...
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY® - global annual revenues of $507 million, an increase of 18% in local …